Redhill Biopharma Valuation
| RDHL Stock | USD 6.74 0.34 5.31% |
At this time, the company appears to be undervalued. Redhill Biopharma holds a recent Real Value of $15.05 per share. The prevailing price of the company is $6.74. Our model determines the value of Redhill Biopharma from analyzing the company fundamentals such as Return On Equity of -17.09, shares owned by institutions of 6.02 %, and Current Valuation of 1.48 M as well as examining its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Redhill Biopharma's valuation include:
Price Book 134.3516 | Enterprise Value 1.5 M | Enterprise Value Ebitda 0.3005 | Price Sales 2.2108 | Forward PE 1.4 K |
Undervalued
Today
Please note that Redhill Biopharma's price fluctuation is somewhat reliable at this time. Calculation of the real value of Redhill Biopharma is based on 3 months time horizon. Increasing Redhill Biopharma's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
The fair value of the Redhill stock is determined by what a typical buyer is willing to pay for full or partial control of Redhill Biopharma. Since Redhill Biopharma is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Redhill Stock. However, Redhill Biopharma's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 6.74 | Real 15.05 | Target 40.0 | Hype 6.64 | Naive 6.19 |
The intrinsic value of Redhill Biopharma's stock can be calculated using various methods such as discounted cash flow or dividend analysis. That value may differ from its market price, which is determined by factors such as investor sentiment, market trends, headlines, and other external factors that may influence Redhill Biopharma's stock price.
Estimating the potential upside or downside of Redhill Biopharma helps investors to forecast how Redhill stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Redhill Biopharma more accurately as focusing exclusively on Redhill Biopharma's fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Redhill Biopharma's intrinsic value based on its ongoing forecasts of Redhill Biopharma's financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Redhill Biopharma's closest peers.
Redhill Biopharma Cash |
|
Redhill Valuation Trend
Knowing Redhill Biopharma's actual value is paramount for traders when making sound investment determinations. Using both Redhill Biopharma's enterprise value as well as its market capitalization is the best way to estimate the value of the company and is usually enough for investors to make market timing decisions.
Redhill Biopharma Total Value Analysis
Redhill Biopharma is at this time forecasted to have valuation of 1.48 M with market capitalization of 8.2 M, debt of 1.17 M, and cash on hands of 28.86 M. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Redhill Biopharma fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.48 M | 8.2 M | 1.17 M | 28.86 M |
Redhill Biopharma Investor Information
The company recorded a loss per share of 302.63. Redhill Biopharma had not issued any dividends in recent years. The entity had 1:25 split on the 20th of August 2024. Based on the key measurements obtained from Redhill Biopharma's financial statements, Redhill Biopharma is performing exceptionally good at this time. It has a great probability to report excellent financial results in December.Redhill Biopharma Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Redhill Biopharma has an asset utilization ratio of 28.26 percent. This suggests that the Company is making $0.28 for each dollar of assets. An increasing asset utilization means that Redhill Biopharma is more efficient with each dollar of assets it utilizes for everyday operations.Redhill Biopharma Ownership Allocation
Roughly 93.98 pct. of Redhill Biopharma outstanding shares are held by general public with 6.02 (%) by third-party entities.Redhill Biopharma Profitability Analysis
The company reported the previous year's revenue of 6.51 M. Net Income was 23.92 M with profit before overhead, payroll, taxes, and interest of 45.25 M.About Redhill Biopharma Valuation
We use absolute and relative valuation methodologies to arrive at the intrinsic value of Redhill Biopharma. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Redhill Biopharma based exclusively on its fundamental and basic technical indicators. By analyzing Redhill Biopharma's financials, quarterly and monthly indicators, and their related drivers, we attempt to find the most accurate representation of Redhill Biopharma's intrinsic value. As compared to an absolute model, our relative valuation model uses a comparative analysis of Redhill Biopharma. We calculate exposure to Redhill Biopharma's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Redhill Biopharma's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 3.1 M | 5.1 M | |
| Pretax Profit Margin | 3.68 | 3.86 | |
| Operating Profit Margin | 1.94 | 2.04 | |
| Net Profit Margin | 3.67 | 3.86 | |
| Gross Profit Margin | 0.47 | 0.49 |
Redhill Biopharma Growth Indicators
Investing in growth stocks can be very risky. If the company such as Redhill Biopharma does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Common Stock Shares Outstanding | 6.5 M | |
| Forward Price Earnings | 1428.5714 |
Redhill Biopharma Current Valuation Indicators
Redhill Biopharma's valuation analysis is a process of estimating the intrinsic value of all assets and outstanding equities. There are different methodologies and models we use to develop the final Redhill Biopharma's valuation. The techniques such as discounted cash flow and fundamental indicators such as book value per share or market capitalization are well known and widely used across most financial advisers and money managers.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Redhill Biopharma, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Redhill Biopharma's valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Redhill Biopharma's worth.When determining whether Redhill Biopharma is a strong investment it is important to analyze Redhill Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Redhill Biopharma's future performance. For an informed investment choice regarding Redhill Stock, refer to the following important reports: Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Redhill Biopharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. For more information on how to buy Redhill Stock please use our How to buy in Redhill Stock guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Redhill Biopharma. If investors know Redhill will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Redhill Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (302.63) | Revenue Per Share 4.733 | Quarterly Revenue Growth (0.28) | Return On Assets (0.45) | Return On Equity (17.09) |
The market value of Redhill Biopharma is measured differently than its book value, which is the value of Redhill that is recorded on the company's balance sheet. Investors also form their own opinion of Redhill Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Redhill Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Redhill Biopharma's market value can be influenced by many factors that don't directly affect Redhill Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Redhill Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Redhill Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Redhill Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.